Press release
Clostridium Difficile Infections Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
Stay ahead with the latest insights! Download DelveInsight's comprehensive Clostridium Difficile Infections Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Clostridium Difficile Infections Pipeline Outlook Report [https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Clostridium Difficile Infections Pipeline Report
* In June 2025, Vedanta Biosciences Inc . announced a study is to evaluate the safety and the Clostridioides difficile infection (CDI) recurrence rate at Week 8 in participants who receive a 14-day course of VE303 or matching placebo. The objectives and endpoints are identical for Stage 1 (recurrent CDI) and Stage 2 (high-risk primary CDI).
* In June 2025, Crestone Inc. announced a research is to evaluate the primary objectives of safety and efficacy (rate of clinical cure) of 2 dosages of CRS3123 (200 mg and 400 mg) administered orally (po) twice daily (bid) and vancomycin administered 125 mg PO 4 times daily (qid) in adults > or equal to 18 years of age with a primary episode or first recurrence of CDI. The study will investigate the plasma concentrations and HRQoL outcomes of CRS3123 and additional efficacy endpoints as secondary objectives.
* DelveInsight's Clostridium Difficile Infections pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Clostridium Difficile Infections treatment.
* The leading Clostridium Difficile Infections Companies such as Acurx Pharmaceuticals, Adiso Therapeutics, Summit Therapeutics, Finch Therapeutics Group, Mikrobiomik Healthcare Company S.L., Crestone, MGB Biopharma, Vedanta Biosciences, Deinove, Biovertis AG, Lumen Bioscience, ImmuniMed, Deinove and others.
* Promising Clostridium Difficile Infections Pipeline Therapies such as VE303, Ibezapolstat, Vancomycin, SER-109, RBX2660, MK-6072, MK-3415A, Fidaxomicin and others.
Discover how the Clostridium Difficile Infections treatment paradigm is evolving. Access DelveInsight's in-depth Clostridium Difficile Infections Pipeline Analysis for a closer look at promising breakthroughs @ Clostridium Difficile Infections Clinical Trials and Studies [https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Clostridium Difficile Infections Emerging Drugs Profile
* VE303: Vedanta Biosciences
VE303 is a potential first-in-class live biotherapeutic product candidate being developed by Vedanta Biosciences to prevent recurrence of Clostridioides difficile infection (CDI). It consists of a rationally-designed, defined bacterial consortium of 8 strains of clonal human commensal bacteria selected for their ability to provide colonization resistance to C. difficile. VE303 is administered orally in capsules and is produced under CGMP conditions from pure, clonal bacterial cell banks, yielding a standardized drug product. In a Phase II study, high-dose VE303 met its primary endpoint of preventing CDI recurrence at eight weeks in patients at high risk of recurrence. VE303 was generally well-tolerated in the study. Vedanta is currently enrolling patients into a pivotal Phase III registrational study called RESTORATiVE303 to evaluate the efficacy and safety of VE303 for the prevention of recurrent CD.
* Ibezapolstat: Acurx Pharmaceuticals
Ibezapolstat (formerly named ACX-362E) is our lead antibiotic candidate. Ibezapolstat is a first-in-class of a new class of Pol IIIC inhibitors which is in clinical development to treat C. difficile infections or CDI. In June 2018, ibezapolstat was designated by the US Food and Drug Administration (FDA) as a Qualified Infectious Disease Product (QIDP) for the treatment of patients with CDI and will be eligible to benefit from the incentives for the development of new antibiotics established under the Generating New Antibiotic Incentives Now (GAIN) Act. In January 2019, FDA granted Fast Track designation to ibezapolstat for the treatment of patients with CDI. The CDC has designated C. difficile as an urgent threat highlighting the need for new antibiotics to treat CDI. Currently, the drug is in the Phase II stage of its development for the treatment of Clostridium Difficile Infections.
The Clostridium Difficile Infections Pipeline Report Provides Insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Clostridium Difficile Infections with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Clostridium Difficile Infections Treatment.
* Clostridium Difficile Infections Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Clostridium Difficile Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Clostridium Difficile Infections market
Explore groundbreaking therapies and clinical trials in the Clostridium Difficile Infections Pipeline. Access DelveInsight's detailed report now! @ New Clostridium Difficile Infections Drugs [https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Clostridium Difficile Infections Companies
Acurx Pharmaceuticals, Adiso Therapeutics, Summit Therapeutics, Finch Therapeutics Group, Mikrobiomik Healthcare Company S.L., Crestone, MGB Biopharma, Vedanta Biosciences, Deinove, Biovertis AG, Lumen Bioscience, ImmuniMed, Deinove and others.
Clostridium Difficile Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Clostridium Difficile Infections Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Clostridium Difficile Infections Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Clostridium Difficile Infections Pipeline Report
* Coverage- Global
* Clostridium Difficile Infections Companies- Acurx Pharmaceuticals, Adiso Therapeutics, Summit Therapeutics, Finch Therapeutics Group, Mikrobiomik Healthcare Company S.L., Crestone, MGB Biopharma, Vedanta Biosciences, Deinove, Biovertis AG, Lumen Bioscience, ImmuniMed, Deinove and others.
* Clostridium Difficile Infections Pipeline Therapies such as VE303, Ibezapolstat, Vancomycin, SER-109, RBX2660, MK-6072, MK-3415A, Fidaxomicin and others.
* Clostridium Difficile Infections Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Clostridium Difficile Infections Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Clostridium Difficile Infections drug development? Find out in DelveInsight's exclusive Clostridium Difficile Infections Pipeline Report-access it now! @ Clostridium Difficile Infections Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Clostridium Difficile Infections: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Clostridium Difficile Infections- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* VE303: Vedanta Biosciences
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Ibezapolstat: Acurx Pharmaceuticals
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug name: Company name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Clostridium Difficile Infections Key Companies
* Clostridium Difficile Infections Key Products
* Clostridium Difficile Infections- Unmet Needs
* Clostridium Difficile Infections- Market Drivers and Barriers
* Clostridium Difficile Infections- Future Perspectives and Conclusion
* Clostridium Difficile Infections Analyst Views
* Clostridium Difficile Infections Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=clostridium-difficile-infections-pipeline-appears-robust-with-20-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/clostridium-difficile-infections-clostridium-difficile-associated-disease-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Clostridium Difficile Infections Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight here
News-ID: 4082133 • Views: …
More Releases from ABNewswire
Gout Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in t …
DelveInsight's, "Gout Pipeline Insight 2025" report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in Gout pipeline landscape. It covers the Gout pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gout pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Gout…
Orthopedic Power Tools Market Growing at 4.15% CAGR, to Reach USD 2.17 Billion b …
Mordor Intelligence has published a new report on the Orthopedic Power Tools market offering a comprehensive analysis of trends, growth drivers, and future projections.
Introduction
Mordor Intelligence, in its latest Orthopedic Power Tools Market report, forecasts the market to grow from USD 1.77billion in 2025 to USD 2.17billion by 2030, at a CAGR of 4.15%. The orthopedic power tools market [https://www.mordorintelligence.com/industry-reports/orthopedic-power-tools-market?utm_source=abnewswire] refers to the segment of medical devices specifically designed for…
Closed System Transfer Devices Market to Reach USD2.67Billion by 2030 at 13.2% C …
Mordor Intelligence has published a new report on the Closed System Transfer Devices Market offering a comprehensive analysis of trends, growth drivers, and future projections.
Introduction
According to a 2025 report by Mordor Intelligence, the Closed System Transfer Devices market size is projected to grow from USD1.43billion in2025 to USD2.67billion by2030, registering a CAGR of 13.20% over the forecast period. The Closed System Transfer Devices (CSTD) market [https://www.mordorintelligence.com/industry-reports/closed-system-transfer-devices-market?utm_source=abnewswire] plays a crucial…
Wastewater Treatment Services Market Industry Analysis by Size, Share, Growth, S …
The Wastewater Treatment Services industry is witnessing steady growth driven by rising industrialization, urban population expansion, and stricter environmental regulations. As water scarcity becomes a global concern, industries and municipalities are increasingly investing in advanced treatment solutions. The market is expected to expand further with innovations in membrane technology, biological treatment, and sustainable practices enhancing service efficiency and compliance.
The global wastewater treatment services market is projected to grow from USD…
More Releases for Clostridium
Clostridium Difficile Diagnostics and Treatment Market – Insights
Clostridium difficile is a disease caused by bacteria. Symptoms of the disease includes diarrhea, nausea, colon inflammation, and others. Clostridium difficile infection affects older adults, and according to Centers for Disease Control and Prevention (CDC), 2015, clostridium difficile infection is the most common healthcare-associated infection. Furthermore, frequent use of antibiotic medication is also responsible for clostridium difficile infection, as antibiotics kill normal flora (good bacteria) and allow for multiplication of…
Clostridium Difficile Diagnostics and Treatment Market – Insights
Clostridium difficile is a disease caused by bacteria. Symptoms of the disease includes diarrhea, nausea, colon inflammation, and others. Clostridium difficile infection affects older adults, and according to Centers for Disease Control and Prevention (CDC), 2015, clostridium difficile infection is the most common healthcare-associated infection. Furthermore, frequent use of antibiotic medication is also responsible for clostridium difficile infection, as antibiotics kill normal flora (good bacteria) and allow for multiplication of…
The Global Clostridium Difficile Infection Treatment Market Driver
Clostridium difficile, which produces gram-positive bacterium, is an anaerobic toxin that gets transmitted through fecal-oral route. Clostridium difficile infection occurs during antibiotic treatment or can be caused due to healthcare associated infection with clinical manifestation ranging from asymptomatic infection to watery diarrhea or serious intestinal condition such as colitis and colonic perforation. This infection can be diagnosed by enzyme immunoassays for toxins or Clostridium difficile glutamate dehydrogenase (GDH) and nucleic…
Clostridium difficile Infections (Clostridium difficile Associated Disease)Marke …
To Understand the pharmaceutical Industry Status worldwide, Market Research Hub (MRH) has included the latest Forecast report titled “Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline Review, H2 2017” to its vast database. This study offers data about the prime regions operating in the pharmaceutical sector, along with their production, consumption, revenue and market share details. Further, the intelligent report also anticipates that the market would grow at a constructive CAGR…
Clostridium difficile Infections (Clostridium difficile Associated Disease)Marke …
To Understand the pharmaceutical Industry Status worldwide, Market Research Hub (MRH) has included the latest Forecast report titled “Clostridium difficile Infections (Clostridium difficile Associated Disease)-Pipeline Review, H2 2017” to its vast database. This study offers data about the prime regions operating in the pharmaceutical sector, along with their production, consumption, revenue and market share details. Further, the intelligent report also anticipates that the market would grow at a constructive CAGR…
Clostridium Vaccine Market : Share, Analysis To 2024
The global clostridium vaccine (animal health) market features a largely consolidated competitive landscape, with the top five companies collectively accounting for a share of over 63% of the overall market in 2015, observes a recent report by Transparency Market Research (TMR). These top vendors, namely Zoetis, Inc., Merck & Co., Sanofi-Aventis, Boehringer Ingelheim, and Eli Lilly and Company hold commanding positions owing to their wide geographic presence and a strong…
